Kennedy Jr. has downplayed the effectiveness of the long-used vaccine and instead promoted the development of new treatments ...

On an investor call Friday, analysts grilled the company over its apparent lack of transparency on the matter.

Sail Biomedicines is shrinking its crew for the second time this year. | Sail Biomedicines is shrinking its crew for the ...

Heartflow is once again looking for a path to go public, with a filing for a Nasdaq IPO. | The former Fierce Medtech Fierce ...

Reeling from the deaths of two patients who took Duchenne muscular dystrophy gene therapy Elevidys, Sarepta is launching a ...

Novartis has ended work on ianalumab in a painful skin condition after the monoclonal antibody failed to meet “predefined ...

The U.K. is establishing a new biosecurity center designed to improve research into potentially pandemic-causing pathogens ...

To secure the antibody, I-Mab is paying $1.8 million upfront to buy Bridge Health, to be followed by noncontingent quarterly ...

The PD-1xVEGF dealmaking wave that has captivated Western pharma companies is now surging within China. | Sino Biopharm said ...

International companies are increasingly inking licensing deals with Chinese biotechs as concerns regarding drug pricing and ...

With GSK kicking its research and development engine into high gear in recent years, a shuffling of the scientific priorities ...

The late-stage readout suggests that HRS9531 can hold its own against Eli Lilly’s blockbuster GLP-1/GIP agonist Zepbound, ...